ALK and non-small cell lung carcinoma: Of 1,192 NSCLC patients with available EGFR mutation test results diagnosed/treated at our institution from May 2012 to April 2017, 442 patients (37.1%) were excluded from the analysis due to insufficient medical data (28.7%), presence of ALK mutations (2.2%), or stage I–IIIA at diagnosis without recurrent disease (6.2%) (Figure 1).